澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

NEURIZON THERAPEUTICS LTD

0.084

0.000

成交量：50.09万

成交额：4.14万

市值：5,868.48万

市盈率：-2.84

高：0.084

开：0.084

低：0.081

收：0.084

52周最高：0.185

52周最低：0.076

股本：6.99亿

流通股本：3.51亿

量比：0.56

换手率：0.14%

股息：- -

股息率：- -

每股收益(TTM):-0.030

每股收益(LYR):-0.034

净资产收益率：-147.09%

总资产收益率：-60.21%

市净率：7.08

市盈率(LYR):-2.47

数据加载中...

总览公司新闻资讯公告

NEURIZON THERAPEUTICS LTD 成功在全部重点市场获得Neurizon®注册商标保护

NEURIZON THERAPEUTICS LTD获准进入Healey ALS Platform Trial 试验预计2025年第四季度启动

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NUZ.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.084,"timestamp":1773983520000,"preClose":0.084,"halted":0,"volume":500920,"delay":0,"changeRate":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":698628681,"eps":-0.029543,"marketStatus":"未开盘","change":0,"latestTime":"03-20 16:12:00 AEDT","open":0.084,"high":0.084,"low":0.081,"amount":41354,"amplitude":0.035714,"askPrice":0.085,"askSize":35294,"bidPrice":0.082,"bidSize":155440,"shortable":3,"etf":0,"ttmEps":-0.029543,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1774220400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.084,"openAndCloseTimeList":[[1773961200000,1773982800000]],"volumeRatio":0.5562536672335026,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.082,"auctionPrice":0.081,"auctionVolume":72685,"auction":3,"marketStatus":"盘后竞价","timestamp":1773896787627}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.21%","roe":"-147.09%","lyrEps":-0.034045,"volumeRatio":0.5562536672335026,"shares":698628681,"dividePrice":0,"high":0.084,"amplitude":0.035714,"preClose":0.084,"low":0.081,"week52Low":0.076,"pbRate":"7.08","psRate":"9.81","week52High":0.185,"institutionHeld":0,"latestPrice":0.084,"committee":0.629914,"eps":-0.029543,"divideRate":0,"volume":500920,"delay":0,"ttmEps":-0.029543,"open":0.084,"prevYearClose":0.085,"prevWeekClose":0.084,"prevMonthClose":0.092,"prevQuarterClose":0.085,"fiveDayClose":0.096,"twentyDayClose":0.095,"sixtyDayClose":0.11,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1104526042","title":"NEURIZON THERAPEUTICS LTD 成功在全部重点市场获得Neurizon®注册商标保护","url":"https://stock-news.laohu8.com/highlight/detail?id=1104526042","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104526042?lang=zh_cn&edition=fundamental","pubTime":"2026-01-20 06:50","pubTimestamp":1768863015,"startTime":"0","endTime":"0","summary":"NEURIZON THERAPEUTICS LTD 宣布，其核心品牌Neurizon®已在全球所有重点市场成功获得注册商标法律保护。这一重要进展标志着公司在知识产权战略布局上取得关键突破，为未来产品全球化商业推广奠定了坚实的法律基础。商标保护的全面落实，不仅有效防范潜在侵权风险，更将显著提升品牌价值与国际市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"1103342926","title":"NEURIZON THERAPEUTICS LTD获准进入Healey ALS Platform Trial 试验预计2025年第四季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1103342926","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103342926?lang=zh_cn&edition=fundamental","pubTime":"2025-10-06 14:08","pubTimestamp":1759730897,"startTime":"0","endTime":"0","summary":"NEURIZON THERAPEUTICS LTD获准进入Healey ALS Platform Trial，该试验预计将于2025年第四季度正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}